Everolimus denied as non-formulary by Kaiser Permanente?

Kaiser Permanente's specific coverage criteria for everolimus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Kaiser Denies Everolimus as Non-Formulary — and What You Can Do

A non-formulary denial means everolimus is not listed on Kaiser's preferred drug list for the plan tier associated with the patient's coverage, or is listed at a tier that requires prior authorization or formulary exception before it will be covered. This is a coverage structure decision, not a clinical rejection — and formulary exceptions are a standard, defined appeals pathway that Kaiser is required to offer under federal and state law.

## The Federal Appeal Framework

Under ACA §2719, all non-grandfathered commercial Kaiser plans must provide internal appeal rights followed by independent external review through a state-approved IRO. The external review window is typically four months after final internal denial. For urgent clinical situations, request expedited review.

For self-funded employer plans, ERISA §503 governs: you are entitled to a full-and-fair review, a written denial citing the specific criteria used, and access to the plan's formulary exception standards.

## The Formulary Exception Standard

Kaiser (and all ACA-compliant plans) must grant a formulary exception when the patient's prescriber establishes that: 1. Every formulary alternative is clinically contraindicated, has already failed, or is otherwise inappropriate for this specific patient, and 2. The requested non-formulary drug is medically necessary for the patient's condition.

The key is documenting individual patient circumstances — not generic preferences.

## Documentation to Gather

• Formulary alternatives tried: Dated pharmacy records, office notes, and clinical outcomes for every formulary-listed drug in the same therapeutic category that was tried before everolimus was requested.
• Clinical explanation of alternatives: Prescriber's documentation of why each formulary alternative is not appropriate for this patient (prior failure, individual clinical factors, or other reasons specific to this patient — documented in the chart).
• Diagnosis and severity documentation: Chart notes, pathology, imaging, and staging records confirming the indication and why timely access to everolimus specifically is necessary.
• FDA prescribing label: The section showing the approved indication matching this patient's diagnosis.
• Prescriber's formulary-exception letter: A letter from the treating specialist explicitly addressing the formulary-exception standard, referencing chart evidence for each point.

## Criteria-Mapping Structure

| Kaiser Formulary Exception Requirement | Patient-Specific Evidence | |---|---| | [Copy from Kaiser's formulary exception policy or the denial letter] | [Dated chart entry, pharmacy record, or clinical note] |

## Practical Next Steps

1. Request Kaiser's formulary exception form and the denial letter with the specific criteria cited. 2. Identify every formulary-listed therapeutic alternative for the relevant indication. 3. Have the prescriber complete the formulary-exception letter, addressing each listed alternative individually. 4. File the formulary exception request/internal appeal with the criteria-mapping table and supporting records attached. 5. If the exception is denied internally, file immediately for independent external review — IRO reviewers apply clinical necessity standards, not the plan's formulary preferences. 6. Check your state's insurance code: many states require expedited formulary exception review for urgent or oncology cases.